Evogene, ELEO collaborate to develop oral small-molecule PCSK9 inhibitors for hyperlipidemia
EVGN•Division of work between the partners
Evogene will use its ChemPass AI platform to design and optimize candidates; Eleo will run biological validation and screening to advance leads toward preclinical work.
Potential next steps and market outlook
The partners will assess later-stage options, including licensing and collaborations with global drugmakers.
The companies cited a PCSK9 inhibitor market forecast to grow from about $4.4 billion in 2025 to more than $23 billion by 2035.
Evogene and Eleo begin PCSK9 inhibitor collaboration
Evogene entered a scientific collaboration with South Korea’s Eleo to discover oral small-molecule inhibitors targeting the PCSK9 pathway for hyperlipidemia.
